You might also be interested in:

ForaCare Suisse AG forms service-oriented partnership with B. Braun (PHOTO)

St. Gallen (ots) - - Partnership to introduce innovative health management technologies. - Initial product offering ...

German Gin Brand 'GINSTR' Expands to Asia

HONG KONG (ots) - - Cross-reference: Picture is available - Over the ...

Germany Sees Red: Eon Becoming a New Energy Monopoly

Hamburg (ots) - - Crossreference: Picture is available at - Analysis ...

01.06.2017 – 14:00

Debiopharm International SA

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Lausanne, Switzerland (ots)

Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors

Debiopharm International SA (Debiopharm -, part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I dose-escalation study evaluating the compound Debio 1347/CH5183284 (FGFR 1,2,3 selective inhibitor). The data will be presented at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting by Martin H. Voss, MD, Medical Oncology at the Memorial Sloan Kettering Cancer Center in New York. "We are very pleased to have reached this milestone and to be able to see these very interesting and promising results presented at the upcoming ASCO meeting. Despite not reaching the MTD, we are confident to have reached the right dose for phase 2 - given the indicators of anti-tumor activity that we have seen", said Chris Freitag, VP Clinical Research & Development.

Oral Abstract Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Title Date and Time Abstract N°

Debio 1347, an oral FGFR inhibitor:    Sat, June 3,       #2500
Results from a first-in-human,         1:15 - 1:27 pm 
phase I dose-escalation study in 
patients with FGFR genomically 
activated advanced solid tumors.              

About Debio 1347/CH5183284

Debio 1347/CH5183284, created by Chugai Pharmaceutical. Co., Ltd., is an orally available small molecule targeting FGFR 1, 2, 3 signaling pathways. Debiopharm International SA completed the dose escalation portion of the first-in-human phase I study. Debio 1347/CH5183284 had a manageable safety profile. Encouraging antitumor activity was seen in several tumor types, mainly in patients with FGFR2 or 3 gene alterations, including fusion events. Efficacy will be further explored in disease-specific and molecularly defined expansion cohort.

About Debiopharm International SA

Part of Debiopharm Group(TM) - a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide. For more information, please visit

We are on Twitter. Follow us @DebiopharmNews at


Debiopharm International SA
Contact Christelle Tur
Communication Coordinator
Tel: +41 (0)21 321 01 11

Original content of: Debiopharm International SA, transmitted by news aktuell

All Releases
Subscribe to Debiopharm International SA
  • Printable version
  • PDF version

Places in this release

Topics in this relase